検索新着情報News
【TargetMol】新製品(2月版)のご紹介
- 2025/03/19
- サプライヤニュース
 |
|
| New Compound | February |
 |
PBRM (17β-HSD1-IN-2) is a selective covalent inhibitor of 17β-HSD1, used in breast cancer and endometriosis research.
Research Areas: Cancer Targets: Epigenetic Reader Domain |
|
Anisodine is an inhibitor of muscarinic acetylcholine receptors (mAChR) with neuroprotective activity, used in research on multiple myeloma and metastatic breast cancer.
Research Areas: Neurological Disease Targets: Endogenous Metabolite |
 |
 |
PF-07328948 is a branched-chain keto acid dehydrogenase kinase (BDK) inhibitor, useful in research on cardiovascular disease (CVD) and metabolic disorders.
|
|
Epiroprim (Ro11-8958) is a selective dihydrofolate reductase (DHFR) inhibitor with antibacterial activity, inhibiting Staphylococcus, Enterococcus, Pneumococcus, and Streptococcus.
Research Areas: Infection Targets: Dihydrofolate reductase(DHFR)；Bacterial |
 |
 |
BMH-7 (Histamine H4 receptor antagonist-2) is a p53 activator with antitumor activity through activation of the p53 pathway.
Research Areas: Others Targets: Others |
|
E2730 is an orally active, selective, and non-competitive GABA transporter 1 (GAT1) inhibitor with antiepileptic activity, used in neurological disease research.
Research Areas: Neurological Disease Targets: GABA Receptor |
 |
 |
A-1211212 (BCL2-IN-1) is a potent and selective Bcl-2 inhibitor. It promotes lymphocyte apoptosis, alters colonic mucosa in mice, and improves inflammation.
Research Areas: Cancer Targets: Bcl-2 Family |
|
|
* {
font-family: Verdana, Alright Sans, Calibri, Arial, Helvetica, Sans-Serif;
}
.compound_name {
font-weight: bold;
font-size: 17px;
padding: 0px 0px 2px 2px;
text-align: left
}
.compound_des {
font-size: 12px;
padding: 3px 0px 3px 0px;
}
.compound_img {
border-style: none;
padding: 2px 2px 2px 2px;
}
.learn_more {
padding: 0px 0px 2px 2px;
font-size: 14px;
font-weight: bold;
color: #D8D8E1;
text-align: right
}
a:link {
color: #4852A9;
}
a:visited {
color: #4852A9;
;
}
a:hover {
color: #4852A9
;
8;
}
a:active {
color: lightgrey
}
.menu {
background: #FFF0FC;
font-size: 13px;
font-weight: bold;
text-align: center;
padding: 20px 20px 20px 20px;
}
.blank_row {
background-color: #D8D8E1
}
.nav_item{
padding: 10px;
display: flex;
justify-content: center;
}
.nav_item> a {
width: 25%;
text-align: center;
}
/* CMS Other Editor Test */
@media only screen and (max-width: 480px){
body { margin: 0; padding: 0; }
}
@media only screen and (max-width: 480px){
table[class=container-table], .bmeheadertext, .container-table{ width: 95% !important;}
}
@media only screen and (max-width: 480px){
.header{font-size: 24px !important;}
}
@media only screen and (max-width: 480px){
.contenttitle{font-size: 20px !important;line-height: 140% !important;}
}
@media only screen and (max-width: 480px){
.contenttext{font-size: 16px !important;line-height: 140% !important;}
}
@media only screen and (max-width: 480px){
.single-col{display: block !important; width: 100% !important; float:left; clear:both;}
}
@media only screen and (max-width: 480px){
img.mobile-img-large { width: 100% !important; height:auto !important;display:block;}
}
@media only screen and (max-width: 480px){
img.bmeRSSImage{max-width:300px; height:auto !important;}
}
@media only screen and (max-width: 480px){
td[class="preheader-table"]{padding: 10px 0 !important;}
}
@media only screen and (max-width: 480px){
div[class="bmeheadertext"]{font-size: 12px !important;line-height: 140% !important;}
}
@media only screen and (max-width: 480px){
td[class="bmefootertext"], div[class="bmefootertext"]{font-size: 12px !important;padding-top: 10px;line-height: 140% !important;}
}
@media only screen and (max-width: 480px){
div[class="bmefooter"] td[width="79%"], div[class="bmefooter"] td[width="21%"]{display: block !important;width: 100%;}
}
@media only screen and (max-width: 480px){
.mobile-footer, .mobile-footer a{ font-size: 13px !important; line-height: 18px !important;}
}
@media only screen and (max-width: 480px){
.mobile-footer{ text-align: center !important;}
}
@media only screen and (max-width: 480px){
div.bmefooter, div.bmeheader{ display:block !important;}
}
@media only screen and (max-width: 480px){
table[class="share-tbl"] { padding-bottom: 15px; width: 100% !important;}
}
@media only screen and (max-width: 480px){
table[class="share-tbl"] td { display: block !important; text-align: center !important; width: 100% !important;}
}
@media only screen and (min-width: 640px){
img.bmeRSSImage{max-width:500px !important; height:auto !important;}
}
/* ---extra-- */
table[width="100%"] { width: 100%; }
table[align="center"] { margin: 0 auto; }
td[align="center"] { text-align: center; }
table[width="640"] { width: 640px; }
.blank_row{ font-size: 1px; height: 12px; padding: 0; line-height: 0; }
.compound_des { line-height: 1; text-align: left; }
TargetMol(ターゲットモル)社について
- 本社所在地
- アメリカ マサチューセッツ州
- URL
- https://www.targetmol.com/
TargetMolは、ボストンに本社を置く低分子およびスクリーニングライブラリのサプライヤです。ライフサイエンス試薬、阻害剤、活性剤、実験用および科学用の天然化合物を提供しています。ポートフォリオには、6,000を超える化合物/阻害剤（カタログ）と80種類を超える化合物ライブラリがあります。